The role of vaginal cuff brachytherapy in endometrial cancer

Harkenrider, Matthew M.; Block, Alec M.; Siddiqui, Z.A.; Small, William

doi:10.1016/j.ygyno.2014.12.036

Cited by 32 publications

(19 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, five gliptins that vary in their pharmacodynamic and pharmacokinetic properties have been approved for clinical use [1, 7, 10]. In our study, 1 mM sitagliptin decreased AN3CA cell proliferation by 60% and blocked invasion and cell cycle progression.…”

Section: Discussionmentioning

confidence: 49%

See 1 more Smart Citation

DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis

Yang

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Dipeptidyl peptidase IV (DPPIV), also known as CD26, is a 110-kDa cell surface glycoprotein expressed in various tissues. DPPIV reportedly plays a direct role in the progression of several human malignancies. DPPIV specific inhibitors are employed as antidiabetics and could potentially be repurposed to enhance anti-tumor immunotherapies. In the present study, we investigated the correlation between DPPIV expression and tumor progression in endometrial carcinoma (EC). DPPIV overexpression altered cell morphology and stimulated cell proliferation, invasion and tumorigenesis in vitro and in vivo. These effects were abrogated by DPPIV knockdown or pharmacological inhibition using sitagliptin. DPPIV overexpression increased hypoxia-inducible factor 1a (HIF-1a) and vascular endothelial growth factor A (VEGFA) expression to promote HIF-1a-VEGFA signaling. Our results indicated that DPPIV accelerated endometrial carcinoma progression and that sitagliptin may be an effective anti-EC therapeutic.

show abstract

Section: Discussionmentioning

confidence: 49%

“…Both EC incidence and patient mortality rates are increasing, with 54,870 new cases and 10,170 deaths reported in 2015 [1]. Although Asian women have a comparatively lower EC risk, incidences of EC in China and Japan are also on the rise [2, 3].…”

Section: Introductionmentioning

confidence: 99%

DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis

Yang

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…As Table 2 shows, even patients that are at lesser risk of recurrence can benefit from VBT. Some of the authors previously published estimates and treatment recommendations based on the available literature to help guide discussions of the benefit of VBT with patients [35]. It is important to estimate the risk of recurrence based on the patient’s risk factors and discuss the risks, benefits, and side effects of both adjuvant therapy and salvage therapy along with potential toxicities.…”

Section: Vaginal Brachytherapymentioning

confidence: 99%

American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review

et al. 2017

Self Cite

View full text Add to dashboard Cite

This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the post-operative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early stage endometrial cancer patients results in very low rates of vaginal recurrence (0–3.1%) with low rates of late toxicity which are primarily vaginal in nature. PORTEC-2 supports that VBT results in non-inferior rates of vaginal recurrence compared to external beam radiotherapy (EBRT) for the treatment of high-intermediate risk patients. VBT as a boost following EBRT, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians both prefer joint decision-making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit in risk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multi-disciplinary setting and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.

show abstract

“…Both the incidence of and mortality due to endometrial cancer are on the rise, and in 2014, 54870 new cases and 10170 deaths are predicted[1]. Women have a 2.6% lifetime risk of developing this malignancy in the US [2].…”

Section: Introductionmentioning

confidence: 99%

Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling

Han

Zhang

Guo

et al. 2015

Gynecologic Oncology

146

109

View full text Add to dashboard Cite

Objectives Obesity and diabetes are well-known risk factors for the development of endometrial cancer. A high rate of aerobic glycolysis represents a key mechanism by which endometrial cancer cells consume glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target whose inhibition has implications for anti-tumor activity in cancer cells. This study aimed to investigate the effect of various concentrations of glucose on cell proliferation in endometrial cancer. Methods ECC-1 and Ishikawa cells were treated with low glucose (1mM), normal glucose (5mM) and high glucose (25mM), and cytotoxicity, apoptosis, cell cycle, adhesion/invasion, and changes of AMPK/mTOR/S6 and MAPK pathways were evaluated. Results Our results revealed that high glucose increased cell growth and clonogenicity in two endometrial cancer cell lines in a dose dependent manner. Low glucose induced the activity of cleaved caspase 3 and caused cell cycle G1 arrest. High glucose increased the ability of adhesion and invasion by decreasing E-Cadherin and increasing Snail expression. In addition, high glucose increased glucose uptake and glycolytic activity through modulating the AMPK/mTOR/S6 and MAPK pathways. Conclusions Our findings suggest that glucose stimulated cell proliferation through multiple complex signaling pathways. Targeting glucose metabolism may be a promising therapeutic strategy in the treatment of endometrial cancer.

show abstract

The role of vaginal cuff brachytherapy in endometrial cancer

Cited by 32 publications

References 61 publications

DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis

DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis

American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review

Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling

Contact Info

Product

Resources

About